NYSE:USNA

USANA Health Sciences Stock Forecast, Price & News

$89.56

+2.89 (+3.33 %)

(As of 01/25/2021 05:06 PM ET)

Add

Compare

Today's Range

$86.51

Now: $89.56▼

$89.60

50-Day Range

$75.28

MA: $78.66▼

$85.63

52-Week Range

$43.01

Now: $89.56▼

$92.26

Volume147,657 shs

Average Volume83,204 shs

Market Capitalization$1.88 billion

P/E Ratio16.59

Dividend YieldN/A

Beta0.98

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

MarketRank^™

Overall MarketRank^™

1.77 out of 5 stars

Medical Sector

145th out of 1,922 stocks

Medicinals & Botanicals Industry

1st out of 33 stocks

2.5 Analyst's Opinion

Consensus Rating
USANA Health Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $107.00, USANA Health Sciences has a forecasted upside of 19.9% from its current price of $89.22.
Amount of Analyst Coverage
USANA Health Sciences has only been the subject of 1 research reports in the past 90 days.

2.2 Community Rank

Outperform Votes
USANA Health Sciences has received 362 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
USANA Health Sciences has received 455 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
USANA Health Sciences has received 55.69% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about USANA Health Sciences and other stocks. Vote “Outperform” if you believe USNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe USNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
USANA Health Sciences does not currently pay a dividend.
Dividend Growth
USANA Health Sciences does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, USANA Health Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $127,055.00 in company stock.
Percentage Held by Insiders
45.40% of the stock of USANA Health Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
54.12% of the stock of USANA Health Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5 Earnings and Valuation

Earnings Growth
Earnings for USANA Health Sciences are expected to grow by 0.93% in the coming year, from $5.40 to $5.45 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of USANA Health Sciences is 16.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.33.
Price to Earnings Ratio vs. Sector
The P/E ratio of USANA Health Sciences is 16.52, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 36.60.
Price to Earnings Growth Ratio
USANA Health Sciences has a PEG Ratio of 0.96. PEG Ratios around 1 indicate that a company is correctly valued.
Price to Book Value per Share Ratio
USANA Health Sciences has a P/B Ratio of 5.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Medicinals & botanicals

Sub-IndustryPersonal Products

SectorMedical

Current SymbolNYSE:USNA

Previous Symbol

CUSIP90328M10

CIK896264

Webwww.usana.com

Phone801-954-7100

Employees1,909

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio2.40

Quick Ratio1.91

Price-To-Earnings

Trailing P/E Ratio16.59

Forward P/E Ratio16.59

P/E Growth0.96

Sales & Book Value

Annual Sales$1.06 billion

Price / Sales1.78

Cash Flow$6.48 per share

Price / Cash Flow13.82

Book Value$16.25 per share

Price / Book5.51

Profitability

EPS (Most Recent Fiscal Year)$4.41

Net Income$100.53 million

Net Margins10.57%

Return on Equity32.91%

Return on Assets22.26%

Miscellaneous

Outstanding Shares21,038,000

Market Cap$1.88 billion

Next Earnings Date2/9/2021 (Confirmed)

OptionableOptionable

$89.56

+2.89 (+3.33 %)

(As of 01/25/2021 05:06 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive USNA News and Ratings via Email

Sign-up to receive the latest news and ratings for USNA and its competitors with MarketBeat's FREE daily newsletter.

USANA Health Sciences (NYSE:USNA) Frequently Asked Questions

How has USANA Health Sciences' stock been impacted by COVID-19?

USANA Health Sciences' stock was trading at $69.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, USNA stock has increased by 27.9% and is now trading at $89.40.
View which stocks have been most impacted by COVID-19.

Is USANA Health Sciences a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" USANA Health Sciences stock.
View analyst ratings for USANA Health Sciences or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than USANA Health Sciences?

Wall Street analysts have given USANA Health Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but USANA Health Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Kevin Guest's approval rating as USANA Health Sciences' CEO?

68 employees have rated USANA Health Sciences CEO Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among USANA Health Sciences' employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is USANA Health Sciences' next earnings date?

USANA Health Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, February 9th 2021.
View our earnings forecast for USANA Health Sciences.

How can I listen to USANA Health Sciences' earnings call?

USANA Health Sciences will be holding an earnings conference call on Tuesday, February 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) issued its quarterly earnings data on Tuesday, October, 20th. The company reported $1.44 EPS for the quarter, topping analysts' consensus estimates of $1.29 by $0.15. The company had revenue of $298.50 million for the quarter, compared to analysts' expectations of $281.80 million. USANA Health Sciences had a trailing twelve-month return on equity of 32.91% and a net margin of 10.57%. The business's revenue was up 14.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.09 earnings per share.
View USANA Health Sciences' earnings history.

How will USANA Health Sciences' stock buyback program work?

USANA Health Sciences declared that its board has initiated a stock buyback program on Wednesday, February 5th 2020, which permits the company to buyback $130,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 9.1% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board of directors believes its shares are undervalued.

What price target have analysts set for USNA?

2 brokerages have issued 1 year target prices for USANA Health Sciences' stock. Their forecasts range from $107.00 to $107.00. On average, they expect USANA Health Sciences' share price to reach $107.00 in the next twelve months. This suggests a possible upside of 19.7% from the stock's current price.
View analysts' price targets for USANA Health Sciences or view Wall Street analyst' top-rated stocks.

Who are some of USANA Health Sciences' key competitors?

Some companies that are related to USANA Health Sciences include The Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Medifast (MED), Prestige Consumer Healthcare (PBH), Inter Parfums (IPAR), Veru (VERU), Revlon (REV) and Nature's Sunshine Products (NATR).
View all of USNA's competitors.

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), The Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

Who are USANA Health Sciences' key executives?

USANA Health Sciences' management team includes the following people:

Mr. Kevin G. Guest, Chairman & CEO (Age 58, Pay $1.39M)
Mr. Jim Brown, Pres (Age 52, Pay $905.81k)
Mr. G. Douglas Hekking, Chief Financial Officer (Age 51, Pay $641.25k)
Dr. Myron W. Wentz, Founder & Chairman Emeritus (Age 80)
Dr. John Cuomo, Exec. Director of Product Devel. & Technology
Mr. Patrique Richards, Exec. Director of Investor Relations & Bus. Devel.
Ms. Ashley Collins, VP of Marketing & PR
Ng Keng Hean, Exec. VP of South Asia
Mr. Sherman Ying, Exec. VP of North Asia
Dr. Brian Dixon, Exec. Director of Health & Science Education

What is USANA Health Sciences' stock symbol?

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Strs Ohio (0.05%), State of Alaska Department of Revenue (0.04%) and Pacer Advisors Inc. (0.03%). Company insiders that own USANA Health Sciences stock include Brent Neidig, Daniel A Macuga, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert A Sinnott, Robert Auciaux, Timothy E Wood and Walter Noot.
View institutional ownership trends for USANA Health Sciences.

Which major investors are selling USANA Health Sciences stock?

USNA stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold USANA Health Sciences company stock in the last year include Brent Neidig, Daniel A Macuga, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert A Sinnott, Timothy E Wood, and Walter Noot.
View insider buying and selling activity for USANA Health Sciences or view top insider-selling stocks.

Which major investors are buying USANA Health Sciences stock?

USNA stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., and Strs Ohio.
View insider buying and selling activity for USANA Health Sciences or or view top insider-buying stocks.

How do I buy shares of USANA Health Sciences?

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is USANA Health Sciences' stock price today?

One share of USNA stock can currently be purchased for approximately $89.40.

How big of a company is USANA Health Sciences?

USANA Health Sciences has a market capitalization of $1.88 billion and generates $1.06 billion in revenue each year. The company earns $100.53 million in net income (profit) each year or $4.41 on an earnings per share basis. USANA Health Sciences employs 1,909 workers across the globe.

What is USANA Health Sciences' official website?

The official website for USANA Health Sciences is www.usana.com.

How can I contact USANA Health Sciences?

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here